Autoimmune Encephalitis Profile - 1, CSF

The autoimmune encephalitis panel performed on cerebrospinal fluid (CSF) aims to detect specific autoantibodies linked to various forms of autoimmune encephalitis. Understanding these antibodies helps diagnose the following types of autoimmune encephalitis and guides treatment decisions.

• NMDA receptor antibodies: Associated with a severe form of AE characterized by seizures, movement disorders, and altered mental status
• AMPA receptor (GluR1 & GluR2) antibodies: Linked to limbic encephalitis, causing memory problems, seizures, and psychiatric symptoms
• GABA B receptor antibodies: Can cause various neurological symptoms, including seizures, movement disorders, and cognitive decline
• VGKC complex antibodies (LGI1, ASPR2): Primarily associated with limbic encephalitis, presenting with memory issues, seizures, and psychiatric symptoms

The Autoimmune Encephalitis Panel-CSF is a specialised diagnostic test designed to detect specific autoantibodies in the cerebrospinal fluid (CSF) that are associated with various types of autoimmune encephalitis. This test plays a crucial role in identifying the exact type of encephalitis, which is essential for developing targeted treatment plans and improving patient outcomes.

By analysing the presence and titers of specific autoantibodies in the CSF, such as anti-NMDA receptor antibodies, anti-LGI1 antibodies, and anti-CASPR2 antibodies, the Autoimmune Encephalitis Panel-CSF helps doctors differentiate between different forms of autoimmune encephalitis.